Capricor Therapeutics (CAPR) Free Cash Flow (2010 - 2026)

Capricor Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$34.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 369.02% year-over-year to -$34.4 million in Q1 2026; TTM through Mar 2026 was -$99.8 million, a 114.01% decrease from a year earlier, with the FY2025 full-year figure at -$72.7 million, down 76.65% from the prior year.
• Free Cash Flow eased to -$34.4 million in Q1 2026 per CAPR's latest filing, from -$25.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $23.5 million in Q1 2022 and bottomed at -$34.4 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$9.6 million (2023), against an average of -$10.1 million.
• Across the five-year window, Free Cash Flow surged 797.47% in 2022 and sank 369.02% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$7.6 million in 2022, then plunged by 59.99% to -$12.2 million in 2023, then retreated by 25.78% to -$15.3 million in 2024, then plunged by 65.07% to -$25.2 million in 2025, then slumped by 36.24% to -$34.4 million in 2026.
• Per Business Quant, the three latest CAPR Free Cash Flow figures stand at -$34.4 million (Q1 2026), -$25.2 million (Q4 2025), and -$19.7 million (Q3 2025).